Literature DB >> 17102998

[Therapy for secondary arthropathies: from psoriasis and Reiter's disease to hemochromatosis].

A Gödde1, U Müller-Ladner.   

Abstract

Arthralgia is one of the most common complaints in Western society. The classification of joint diseases with respect to genesis is crucial for the determination of adequate treatment. For inflammatory arthropathies, treatment options have expanded significantly over the last decade. This review summarizes the current treatment of psoriatic arthritis and Reiter's disease, both belonging to the spectrum of seronegative spondyloarthropathies. Regardless of our increasing knowledge of chondrogenesis, the treatment of osteoarthritis is still more or less symptomatic. Premature age of onset and the atypical joint distribution of osteoarthritis should bring metabolic diseases, for example hemochromatosis, into consideration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17102998     DOI: 10.1007/s00108-006-1754-0

Source DB:  PubMed          Journal:  Internist (Berl)        ISSN: 0020-9554            Impact factor:   0.743


  23 in total

1.  TNFalpha therapy in psoriatic arthritis and psoriasis.

Authors:  P Mease
Journal:  Ann Rheum Dis       Date:  2004-07       Impact factor: 19.103

Review 2.  Reactive arthritis.

Authors:  M Leirisalo-Repo
Journal:  Scand J Rheumatol       Date:  2005 Jul-Aug       Impact factor: 3.641

3.  A comparison of cyclosporine, sulfasalazine, and symptomatic therapy in the treatment of psoriatic arthritis.

Authors:  C Salvarani; P Macchioni; I Olivieri; A Marchesoni; M Cutolo; G Ferraccioli; F Cantini; F Salaffi; A Padula; C Lovino; L Dovigo; G Bordin; C Davoli; G Pasero; O D Alberighi
Journal:  J Rheumatol       Date:  2001-10       Impact factor: 4.666

4.  Comparison of sulfasalazine and placebo in the treatment of reactive arthritis (Reiter's syndrome). A Department of Veterans Affairs Cooperative Study.

Authors:  D O Clegg; D J Reda; M H Weisman; J J Cush; F B Vasey; H R Schumacher; E Budiman-Mak; D J Balestra; W D Blackburn; G W Cannon; R D Inman; F P Alepa; E Mejias; M R Cohen; R Makkena; M L Mahowald; J Higashida; S L Silverman; N Parhami; J Buxbaum; C M Haakenson; R H Ward; B J Manaster; R J Anderson; W G Henderson
Journal:  Arthritis Rheum       Date:  1996-12

Review 5.  Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials.

Authors:  Tim Bongartz; Alex J Sutton; Michael J Sweeting; Iain Buchan; Eric L Matteson; Victor Montori
Journal:  JAMA       Date:  2006-05-17       Impact factor: 56.272

6.  The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment.

Authors:  Ferdinand C Breedveld; Michael H Weisman; Arthur F Kavanaugh; Stanley B Cohen; Karel Pavelka; Ronald van Vollenhoven; John Sharp; John L Perez; George T Spencer-Green
Journal:  Arthritis Rheum       Date:  2006-01

7.  Randomized, double-blind, placebo controlled trial of low-dose pulse methotrexate in psoriatic arthritis.

Authors:  R F Willkens; H J Williams; J R Ward; M J Egger; J C Reading; P J Clements; E S Cathcart; C O Samuelson; M A Solsky; S B Kaplan
Journal:  Arthritis Rheum       Date:  1984-04

8.  Psoriatic arthritis: clinical response and side effects to methotrexate therapy.

Authors:  L R Espinoza; L Zakraoui; C G Espinoza; F Gutiérrez; L J Jara; L H Silveira; M L Cuéllar; P Martínez-Osuna
Journal:  J Rheumatol       Date:  1992-06       Impact factor: 4.666

9.  Comparison of cyclosporin A and methotrexate in the treatment of psoriatic arthritis: a one-year prospective study.

Authors:  A Spadaro; V Riccieri; A Sili-Scavalli; F Sensi; E Taccari; A Zoppini
Journal:  Clin Exp Rheumatol       Date:  1995 Sep-Oct       Impact factor: 4.473

10.  Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial.

Authors:  J Peter Kaltwasser; Peter Nash; Dafna Gladman; Cheryl F Rosen; Frank Behrens; Peter Jones; Jürgen Wollenhaupt; Franziska G Falk; Philip Mease
Journal:  Arthritis Rheum       Date:  2004-06
View more
  1 in total

Review 1.  [Biological therapy for the treatment of rheumatic diseases].

Authors:  M Pierer; C Baerwald
Journal:  Internist (Berl)       Date:  2008-08       Impact factor: 0.743

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.